Feb 21 (Reuters) - Catalyst Pharmaceuticals Inc, targeted by U.S. Senator Bernie Sanders for high drug prices, said on Thursday that prices of its treatment for a rare neurological disorder were “in line” with similar products in the industry.
Sanders this month wrote to the Florida-based drugmaker asking it to justify its $375,000-per-year price for Firdapse, a medication that for years has been available for free.
Catalyst also said it spends "millions of dollars per year" evaluating Firdapse in clinical trials testing it in other diseases. (bit.ly/2NkmIRU) (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar)